Radiography and pathological responses
PD, tumor, SD, fibrosis
TUMOR, PRIMARY TUMOR, RESIDUAL TUMOR, DISEASE, FIBROSIS, REGRESSION, INFILTRATED
After three cycles of neoadjuvant treatment, three patients achieved complete response (CR), 33 had a partial response (PR), and nine had stable disease (SD), according to RECIST 1.1. No patients developed progressive disease (PD). The objective response rate (ORR) was 80.0% (95% confidence interval [CI], 65.4–90.4%) (Fig. Clinical and pathological responses to neoadjuvant camrelizumab combined with chemotherapy. Among the 42 patients who underwent surgery, postoperative pathological results showed median tumor regression of 90% (range, 10–100%). A total of 27 (64.3%; 95% CI, 48–78.4%) patients had an MPR in the primary tumor. pCR was achieved in 14 (33.3%; 95% CI 19.6–49.5%) cases, of whom 13 (92.2%) had no residual tumor in either primary tissue or lymph node (Fig. Clinical response to neoadjuvant immunochemotherapy. Surgical tissues obtained from pCR or MPR patients were infiltrated by a large number of neutrophils and macrophages, fibrosis, and cholesterol clefts. Besides, we also observed classical TLSs, which have been reported to be associated with a favorable prognosis after immunotherapy [